The My EpiPen Savings Card®

It’s a savings offer that can provide patients up to $300* in out-of-pocket savings for each EpiPen 2-Pak® carton—up to three cartons (six Auto-Injectors) per prescription fill, so patients have immediate access to an EpiPen 2-Pak® in multiple locations.

Patients can find out if they’re eligible and download the MyEpiPen Savings Card® here

Mylan's MyGenericEAI Savings Card

It's a savings offer that can provide patients up to $25* in out-of-pocket savings for each two-pack carton of Mylan's Epinephrine Injection, USP Auto-Injector (Mylan’s authorized generic to EpiPen®)—up to three cartons (six Auto-Injectors) per prescription fill, so patients have immediate access to a two-pack in multiple locations.

Patients can find out if they’re eligible and download the MyGenericEAI Savings Card here

*Certain restrictions apply. See full Terms and Conditions for My EpiPen Savings Card® here and MyGenericEAI Savings card here. These offers are not valid for patients covered by Medicare, Medicaid or any other federal or state funded healthcare program or where prohibited by law. Mylan Specialty L.P. reserves the right to amend or end this program at any time without notice.

Mylan’s Patient Assistance Program

Mylan has recently enhanced its Patient Assistance Program to help increase access to EpiPen®. To enroll, patients must complete the Patient Assistance Program form with their physician. Patients can obtain additional information on the program by emailing customer.service@mylan.com or calling Mylan Customer Relations at 1-800-395-3376 to speak with a representative.

Patient eligibility

To participate in the program, patients must meet the eligibility criteria set forth below:

  • The patient must be a US citizen or a legal resident living in the United States.
  • The patient's gross yearly household income must fall below 400% of the current federal poverty guidelines, based upon family size. Verification documents will be required.

    Approved Documents: 1040, 1040EZ, W2, 4506-T, SSI Statement, Disability Statement, or Statement From Physician, Nurse, or Patient Advocate, or Certified Notarized Statement From the Applicant

  • The patient must meet one of the following conditions:
    • The patient must not have prescription insurance coverage through Medicaid, Medicare Part D, TriCare, a qualified health plan purchased on a state-based, partnership, or federally facilitated exchange, or any other public or private program or insurer. Verification documents will be required.
      Approved Documents: Denial Letter, Termination Statement, Statement From Physician, Nurse, or Patient Advocate, or Certified Notarized Statement From the Applicant.
    • The patient has commercial prescription drug coverage only for generic products and the patient must not have prescription insurance coverage through any state or federally funded program, including, without limitation, Medicare, Medicaid, TriCare or Medicare Part D. Verification documents will be required.
      Approved Documents: Denial Letter, Termination Statement, Statement From Physician or Nurse, or Verification of Applicant's Coverage From the Insurer.

    Download Form

EpiPen4Schools®

With the EpiPen4Schools® program, Mylan Specialty L.P. offers four free EpiPen® (epinephrine injection, USP) or EpiPen Jr® (epinephrine injection, USP) Auto-Injectors, upon qualification, which includes having a valid prescription, to public and private kindergarten, elementary, middle and high schools in the US.

To participate in EpiPen4Schools®, a school nurse or other authorized school representative must visit www.EpiPen4Schools.com to download the order and certification form, and then fax or email the form with a valid prescription to 1-973-718-4328 or info@bioridgepharma.com Alternatively, school representatives can call 1-973-845-7600 to speak with a live representative. There is no requirement for a school to purchase additional EpiPen® Auto-Injectors or any other Mylan Specialty products.

Share This Site

Special Offers

Mylan offers Access and Savings Programs for eligible patients.

There’s only one recommended first line treatment for anaphylaxis.

More Important Safety Information

EpiPen® (epinephrine injection, USP) 0.3 mg and EpiPen Jr® (epinephrine injection, USP) 0.15 mg Auto-Injectors are intended for immediate administration as emergency supportive therapy only and are not intended as a substitute for immediate medical or hospital care. In conjunction with the administration of epinephrine, the patient should seek immediate medical or hospital care. More than two sequential doses of epinephrine should only be administered under direct medical supervision.

EpiPen® and EpiPen Jr® should only be injected into the anterolateral aspect of the thigh. Do not inject intravenously, into buttock, or into digits, hands, or feet. Instruct caregivers to hold the leg of young children firmly in place and limit movement prior to and during injection to minimize risk of injection-related injury.

Rare cases of serious skin and soft tissue infections have been reported following epinephrine injection. Advise patients to seek medical care if they develop symptoms of infection such as persistent redness, warmth, swelling, or tenderness at the injection site.

Epinephrine should be used with caution in patients with heart disease, and in patients who are on drugs that may sensitize the heart to arrhythmias, because it may precipitate or aggravate angina pectoris and produce ventricular arrhythmias. Arrhythmias, including fatal ventricular fibrillation, have been reported, particularly in patients with underlying cardiac disease or taking cardiac glycosides, diuretics, or anti-arrhythmics.

Patients with certain medical conditions or who take certain medications for allergies, depression, thyroid disorders, diabetes, and hypertension, may be at greater risk for adverse reactions. Common adverse reactions to epinephrine include anxiety, apprehensiveness, restlessness, tremor, weakness, dizziness, sweating, palpitations, pallor, nausea and vomiting, headache, and/or respiratory difficulties.

Indications

EpiPen® and EpiPen Jr® Auto-Injectors are indicated in the emergency treatment of Type I allergic reactions, including anaphylaxis, to allergens, idiopathic and exercise-induced anaphylaxis, and in patients with a history or increased risk of anaphylactic reactions. Selection of the appropriate dosage strength is determined according to body weight.

Please see the full Prescribing Information and Patient Information.

For additional information please contact us at 800-395-3376.

References

  1. EpiPen [prescribing & patient information]. Morgantown, WV: Mylan Specialty LP; 2017.
  2. Epinephrine Injection, USP [prescribing & patient information]. Morgantown, WV: Mylan Specialty LP; 2017.
  3. Simons FE. Anaphylaxis. J Allergy Clin Immunol. 2010;125(2)(suppl 2):S161-S181.
  4. Simons FE, Ardusso LR, Bilὸ MB, et al; World Allergy Organization. World Allergy Organization guidelines for the assessment and management of anaphylaxis. World Allergy Organ J. 2011;4(2):13-37.
  5. Boyce JA, Assa’ad A, Burks AW, et al. Guidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panel. J Allergy Clin Immunol. 2010;126(6)(suppl):S1-S58.
  6. Dinakar C. Anaphylaxis in children: current understanding and key issues in diagnosis and treatment. Curr Allergy Asthma Rep. 2012;12(6):641-649.
  7. Lieberman P, Nicklas RA, Randolph C, et al. Anaphylaxis—a practice parameter update 2015. Ann Allergy Asthma Immunol. 2015;115(5):341-384.
  8. Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report—second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006;117(2):391-397.
EpiPen® & EpiPen Jr® (epinephrine injection, USP) Auto-Injectors 0.3/0.15mg

You are now leaving Mylan Specialty's website.

The website you are about to access is not owned or controlled by Mylan Specialty.

MYLAN SPECIALTY ASSUMES NO RESPONSIBILITY FOR, AND MAKES NO REPRESENTATION AS TO THE ACCURACY OF, ANY CONTENT CONTAINED ON THE WEBSITE YOU ARE ABOUT TO ACCESS.

OK

This site is intended for US healthcare professionals.

If you are a patient, please check out our site for patients.